Основная статистика
| LEI | 5299007STZTNN32O9920 |
| CIK | 1689813 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biohaven Ltd.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| October 14, 2022 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-38080 Biohaven Pharmaceutical Holding Company Ltd. (Exact name of re |
|
| October 4, 2022 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on October 17, 2022, pursuant to the provisions of Rule 12d2-2 (a). |
|
| October 3, 2022 |
As filed with the Securities and Exchange Commission on October 3, 2022 As filed with the Securities and Exchange Commission on October 3, 2022 Registration No. |
|
| October 3, 2022 |
As filed with the Securities and Exchange Commission on October 3, 2022 As filed with the Securities and Exchange Commission on October 3, 2022 Registration No. |
|
| October 3, 2022 |
As filed with the Securities and Exchange Commission on October 3, 2022 As filed with the Securities and Exchange Commission on October 3, 2022 Registration No. |
|
| October 3, 2022 |
As filed with the Securities and Exchange Commission on October 3, 2022 As filed with the Securities and Exchange Commission on October 3, 2022 Registration No. |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| October 3, 2022 |
Exhibit 3.1 NO: 1792178 BRITISH VIRGIN ISLANDS BVI BUSINESS COMPANIES ACT 2004 MEMORANDUM & ARTICLES OF ASSOCIATION OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. INCORPORATED THIS 25TH DAY OF SEPTEMBER 2013 AMENDED AND RESTATED THIS 20TH DAY OF JANUARY 2014 AMENDED AND RESTATED THIS 28TH DAY OCTOBER 2016 AMENDED THIS 21ST DAY OF APRIL 2017 AMENDED AND RESTATED THIS 8TH DAY OF MAY 2017 AMENDED AN |
|
| October 3, 2022 |
As filed with the Securities and Exchange Commission on October 3, 2022 As filed with the Securities and Exchange Commission on October 3, 2022 Registration No. |
|
| September 29, 2022 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| September 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 23, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2022 Biohaven Pharmaceutical Holding Company Ltd. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38080 Not applicable (State or other |
|
| September 19, 2022 |
Filed Pursuant to 424(b)(7) Registration No. 333-253946 Prospectus Supplement (To Prospectus dated March 5, 2021) Common Shares This prospectus supplement supplements our prospectus dated March 5, 2021 and registers the resale of an aggregate of 493,254 of our common shares issued to Knopp Biosciences LLC (the ?selling shareholder?) under the Purchase Agreement (as defined herein) dated February 2 |
|
| September 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| September 19, 2022 |
Biohaven Announces Record Date for Anticipated Spin-Off Exhibit 99.1 Biohaven Announces Record Date for Anticipated Spin-Off New Haven, Connecticut ? September 18, 2022 ? Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (?Biohaven?) today announced that it has set a record date of September 26, 2022 (the ?Record Date?) for the previously announced spin-off by Biohaven of its Biohaven Ltd. (?SpinCo?) subsidiary, which will own the Kv7 ion chann |
|
| September 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| September 19, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-3, 424(b)(7) (Form Type) Biohaven Pharmaceutical Holding Company Ltd. |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Rule 14a-101) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definit |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Rule 14a-101) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definit |
|
| August 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| August 5, 2022 |
Exhibit 99.1 BIOHAVEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS DEVELOPMENTS ?Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission ("FTC"), with respect to the previously announced Pfizer Inc. acquisition of Biohaven Pharmaceutical Holding Company Ltd.; preliminary proxy statement has been filed with the |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Rule 14a-101) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definit |
|
| July 1, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Biohaven Pharmaceutical Holding Company Ltd. |
|
| June 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Biohaven Pharmaceutical Holding Co. Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G11196105 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Biohaven Pharmaceutical Holding Co. Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G11196105 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 11, 2022 |
Exhibit 2.2 SEPARATION AND DISTRIBUTION AGREEMENT BY AND AMONG BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD., BIOHAVEN RESEARCH LTD., AND, SOLELY WITH RESPECT TO SECTION 2.7(B), SECTION 2.10, SECTION 4.2, SECTION 4.3, SECTION 4.5(C), SECTION 4.7, SECTION 5.1(A), SECTION 6.6(I), SECTION 8.3, SECTION 8.6, AND SECTION 8.7, PFIZER INC. Dated as of May 9, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITION |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 11, 2022 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among PFIZER INC., BULLDOG (BVI) LTD. and BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD., Dated as of May 9, 2022 Table of Contents Page SECTION 1 - THE MERGER 2 1.1. The Merger 2 1.2. Effective Time 2 1.3. The Closing 2 1.4. Directors and Officers of the Surviving Company 3 1.5. Subsequent Actions 3 1.6. Registered Agent 3 SECTION 2 - CONVERSION OF SE |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 11, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 10, 2022 |
Exhibit 99.1 BIOHAVEN REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND REPORTS RECENT BUSINESS DEVELOPMENTS ?Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven ?Record reported revenues of $319 million ?NURTEC? ODT (rimegepant) TRx volumes grew 8% versus the fourth quarter |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 10, 2022 |
Exhibit 99.1 Pfizer to Acquire Biohaven Pharmaceuticals Pfizer to commercialize NURTEC? ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need Expands Pfizer?s innovative Internal Medicine pipeline to drive enhanced growth through 2030 and beyond Biohaven common shareholders will receive $148.50 per Biohaven share in cash, plus |
|
| May 10, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 10, 2022 |
Exhibit 2.1 EXECUTION VERSION MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among BIOHAVEN THERAPEUTICS LTD., KNOPP BIOSCIENCES LLC, CHANNEL BIOSCIENCES, LLC and BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD., solely for the purpose of Section 9.14 Dated as of FEBRUARY 24, 2022 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MA |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Biohaven Pharmaceutical Holding Co. Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G11196105 (CUSIP Number) April 29, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| April 29, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 25, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. As of December 31, 2021 Name Jurisdiction of Incorporation Biohaven Specialty Pharmaceutical Ltd. British Virgin Islands Biohaven Therapeutics Ltd. British Virgin Islands Biohaven Pharmaceuticals, Inc. Delaware BioShin Limited Cayman Islands BioShin Hong Kong Limited Hong Kong BioShin (Shanghai) Consulting Services Co., Limi |
|
| February 25, 2022 |
Exhibit 99.1 BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ?NURTEC ODT? (rimegepant) net product revenue was $190.0 million for the fourth quarter of 2021 and $462.5 million for full year 2021 with over 1,600,000 prescriptions from product launch to date ?Biohaven received positive opinion recommending the granting of a marketing authorizatio |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| February 25, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| February 25, 2022 |
Exhibit 10.42 AMENDMENT NO. 4 TO FINANCING AGREEMENT This AMENDMENT NO. 4 TO FINANCING AGREEMENT, dated as of December 28, 2021 (this ?Amendment?), is made by and among BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD., a BVI business company limited by shares incorporated under the laws of the British Virgin Islands with company number 1792178 (the ?Company? or ?BVI Borrower?), BIOHAVEN PHARMACEUTICAL |
|
| February 25, 2022 |
Exhibit 10.41 AMENDMENT NO. 1 TO DELAWARE EMPLOYMENT AGREEMENT This Amendment No. 1 to Delaware Employment Agreement (this ?Amendment?) is dated as of December 14, 2021, by and between Biohaven Pharmaceutical, Inc., a Delaware corporation (the ?Company?), and James Engelhart, an individual (the ?Executive?). WHEREAS, the Company and the Executive entered into an Employment Agreement, effective as |
|
| February 11, 2022 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Biohaven Pharmaceutical Holding Co. Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G11196105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Biohaven Pharmaceutical Holding Co. Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G11196105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| January 10, 2022 |
Exhibit 99.1 BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT, MARKET LEADING NOVEL MIGRAINE THERAPY - NURTEC? ODT achieved preliminary net product revenue of approximately $190 million for the fourth quarter of 2021 - Preliminary net product revenue for NURTEC ODT in 2021 totaled approximately $462 million - NURTEC ODT continues its market leadership position |
|
| January 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 Biohaven Pharmaceutical Holding Company Ltd. |
|
| January 7, 2022 |
Exhibit 99.1 Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States Transaction triggers total upfront payment to Biohaven of $500 million NEW HAVEN, Conn. and NEW YORK, Jan. 5, 2022 /PRNewswire/ - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have comp |
|
| December 30, 2021 |
Exhibit 10.1 Biohaven Pharmaceutical Holding Company Ltd. Restricted Share Units 2022 Deferral Election Agreement for Executives Please complete this Agreement and return a signed copy to George Clark no later than December 31, 2021. Name: Last 4 digits of SS#: I hereby elect to defer the settlement date of the Restricted Share Units to be granted to me by Biohaven Pharmaceutical Holding Company L |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| December 9, 2021 |
Exhibit 99.2 Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application - Intranasal zavegepant 10 mg met the study?s co-primary endpoints and demonstrated statistically significant superiority versus placebo on a total of 15 consecutive, prespecified primary and |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| December 9, 2021 |
Consulting Agreement, dated December 5, 2021, between the Company and Declan Doogan. Exhibit 10.1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. CONSULTING AGREEMENT Consulting Agreement (?Agreement?) dated as of December 5, 2021 (?Effective Date?) by and among Declan Doogan (?Consultant?) and Biohaven Pharmaceutical Holding Company Ltd., a company organized under the laws of the Territory of the British Virgin Islands (?Biohaven?) in connection with Consultant's consulting services |
|
| December 9, 2021 |
Exhibit 99.1 BIOHAVEN NAMES CEO VLAD CORIC, MD, CHAIRMAN OF THE BOARD OF DIRECTORS AND MATTHEW BUTEN, CHIEF FINANCIAL OFFICER ?Board Chairman Declan Doogan, MD and CFO James Engelhart both to retire NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of commercial and innovative, late-stage product ca |
|
| December 9, 2021 |
Employment Agreement, dated December 8, 2021, between the Company and Matthew Buten. EXHIBIT 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is effective as of December 8, 2021 (the ?Effective Date?), by and between BIOHAVEN PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and MATTHEW BUTEN, an individual resident of the State of New York (the ?Executive?). WHEREAS, the Company and Executive desire to enter into this Agreement pursuant to which |
|
| November 26, 2021 |
CALCULATION OF REGISTRATION FEE Filed Pursuant to 424(b)(7) Registration No. 333-253946 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount Registered Proposed Maximum Offering Price Per Share(1) Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Shares, no par value 29,297 $108.73 $3,185,462.81 $295.29 (1) Estimated solely for purposes of calculating the registration f |
|
| November 26, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| November 12, 2021 |
Exhibit 10.3 EXECUTION VERSION SUBSCRIPTION AGREEMENT BY AND BETWEEN PFIZER INC. AND BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. Dated November 9, 2021 TABLE OF CONTENTS Page 1. Definitions 1 1.1 Defined Terms 1 1.2 Interpretation 5 2. Purchase and Sale of Common Shares 6 2.1 Closing 6 3. Closing Date; Deliverables 6 3.1 Closing Date 6 3.2 Deliverables 7 4. Representations and Warranties of the C |
|
| November 12, 2021 |
Exhibit 10.4 EXECUTION VERSION AMENDMENT NO. 3 AND LIMITED CONSENT TO FINANCING AGREEMENT This AMENDMENT NO. 3 AND LIMITED CONSENT TO FINANCING AGREEMENT, dated as of November 9, 2021 (this ?Amendment?), is made by and among BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD., a BVI business company limited by shares incorporated under the laws of the British Virgin Islands with company number 1792178 (t |
|
| November 12, 2021 |
Exhibit 10.2 Execution Version [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) CUSTOMARILY AND ACTUALLY TREATED BY THE REGISTRANT AS PRIVATE OR CONFIDENTIAL. SUBLICENSE AGREEMENT BY AND AMONG PFIZER IRELAND PHARMACEUTICALS, BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD., BIOSHIN LTD., AND BIOHAVEN PHARMA |
|
| November 12, 2021 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (including the exhibits and schedules hereto, each as may be amended, restated or otherwise modified from time to time, this ?Agreement?) is made and entered into as of November 9, 2021, by and between Biohaven Pharmaceutical Holding Company Ltd., a business company formed under the laws of the territory o |
|
| November 12, 2021 |
Exhibit 10.1 Execution Version [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) CUSTOMARILY AND ACTUALLY TREATED BY THE REGISTRANT AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT BY AND AMONG PFIZER IRELAND PHARMACEUTICALS, BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD., BIOHAVEN PHARMACEU |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| November 9, 2021 |
Exhibit 99.1 BIOHAVEN REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS - NURTEC? ODT (rimegepant) continues to exceed expectations, reporting $136 million in net product revenue for the third quarter of 2021, totaling approximately $336 million in revenues and over 1,100,000 prescriptions from product launch to date - NURTEC ODT continues to be market leader for new or |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| November 9, 2021 |
Exhibit 99.1 Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States ?Rimegepant, commercialized as Nurtec? ODT in the U.S., is the first and only oral CGRP (calcitonin gene-related peptide) receptor antagonist for the acute and preventive treatment of migraine ?Biohaven to receive tiered double-digit royalties on ex-U.S. net sales as wel |
|
| November 9, 2021 |
EXHIBIT 10.1 Conformed Through Amendment No. 2 EXECUTION VERSION ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(B)(4) and 240.24b-2 FINANCING AGREEMENT dated as of August 7, 2020 as amended by that certain Amendment No. 1 to Financing Agreement dated as of March 1, 2021 and that certain Amendment No. 2 to Financing Agreement dated as of September 30 |
|
| October 6, 2021 |
Exhibit 99.1 BIOHAVEN ANNOUNCES PRELIMINARY 3Q2021 NET PRODUCT REVENUE FOR NURTEC ODT, THE FIRST AND ONLY MIGRAINE MEDICATION FOR BOTH ACUTE AND PREVENTIVE TREATMENT - NURTEC? ODT achieved preliminary net product revenue of approximately $136 million for the third quarter of 2021 - Launch to date net product revenue for NURTEC ODT is approximately $336 million with over 1,000,000 prescriptions fil |
|
| October 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| October 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| September 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| September 27, 2021 |
NYSE:BHVN Ellie, living with migraine ? 2021 Biohaven Pharmaceuticals. All rights reserved. Investor Presentation | September 2021 neuroinnovation Disclaimer This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including: statements about Biohaven Pharmaceutical Holding Company Ltd. (The ?Company?) and our plans relating |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| August 9, 2021 |
Exhibit 99.1 BIOHAVEN REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS - NURTEC? ODT (rimegepant) becomes the first oral CGRP targeting agent approved for the prevention of migraine, and is the only migraine medication now approved for both acute and preventive treatment - NURTEC ODT brand performance continues to exceed expectations, reporting $93 million in net prod |
|
| July 7, 2021 |
BIOHAVEN ANNOUNCES PRELIMINARY 2Q2021 NET PRODUCT REVENUE FOR NURTEC ODT BIOHAVEN ANNOUNCES PRELIMINARY 2Q2021 NET PRODUCT REVENUE FOR NURTEC ODT - NURTEC? ODT achieved preliminary net product revenue of approximately $XX. |
|
| July 7, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (AMENDMENT NO. |
|
| July 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| July 7, 2021 |
BIOHAVEN ANNOUNCES PRELIMINARY 2Q2021 NET PRODUCT REVENUE FOR NURTEC ODT, THE FIRST AND ONLY MIGRAINE MEDICATION FOR BOTH ACUTE AND PREVENTIVE TREATMENT - NURTEC? ODT achieved preliminary net product revenue of approximately $93 million for the second quarter of 2021 - Launch to date net product revenue for NURTEC ODT is approximately $200 million with over 750,000 prescriptions filled since initial product launch in March 2020, and NURTEC ODT now accounts for 51. |
|
| June 29, 2021 |
NYSE:BHVN Ellie, living with migraine ? 2021 Biohaven Pharmaceuticals. All rights reserved. Leerink Fireside Chat | June 2021 neuroinnovation Exhibit 99.1 Disclaimer This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including: statements about Biohaven Pharmaceutical Holding Company Ltd. (The ?Company?) and our plans r |
|
| June 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| June 22, 2021 |
Biohaven Appoints Kishen Mehta to Board of Directors Biohaven Appoints Kishen Mehta to Board of Directors NEW HAVEN, Conn., June 17, 2021 - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of Kishen Mehta, Portfolio Manager at Suvretta Capital Management, LLC, to its Board of Directors ("Board"). Mr. Mehta previously served as a strategic advisor to Biohaven. Declan Doogan, M.D., Chairman of Biohaven's Board |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| June 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| June 1, 2021 |
Exhibit 99.1 FDA Approves Biohaven?s NURTEC? ODT (rimegepant) for Prevention: Now the First and Only Migraine Medication for both Acute and Preventive Treatment ?NURTEC ODT 75 mg is the first oral CGRP antagonist approved to prevent migraine ?NURTEC ODT 75 mg is now the only migraine medication approved to both treat acute migraine attacks and help prevent future migraine attacks ?In a pivotal Pha |
|
| May 11, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 10, 2021 |
Exhibit 99.1 As a result of an inadvertent error, the version of the earnings release Biohaven Pharmaceutical Holding Company Ltd. (?Biohaven?) issued before market open on May 10, 2021 (the ?Original Earnings Release?) included certain inaccurate financial and operational data. The financial and operational data included in the earnings call and slide deck available on the company website prior t |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| April 8, 2021 |
BIOHAVEN ANNOUNCES PRELIMINARY 1Q2021 NET PRODUCT REVENUE FOR NURTEC ODT BIOHAVEN ANNOUNCES PRELIMINARY 1Q2021 NET PRODUCT REVENUE FOR NURTEC ODT - NURTEC® ODT achieved preliminary net product revenue of approximately $43. |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| March 17, 2021 |
Filed Pursuant to 424(b)(5) Registration No. 333-232167 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be Registered(1) Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Shares, no par value 3,089,370 $76.00 $234,792,120 $25,616 (1) Includes 402,961 Common Shares that the underwriter has the option to purcha |
|
| March 17, 2021 |
Exhibit 1.1 2,686,409 Shares BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. COMMON SHARES, WITHOUT PAR VALUE UNDERWRITING AGREEMENT March 15, 2021 March 15, 2021 Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198 Ladies and Gentlemen: Biohaven Pharmaceutical Holding Company Ltd., a British Virgin Islands (?BVI?) business company (the ?Company?), proposes to issue and sell to Gol |
|
| March 15, 2021 |
Biohaven Pharmaceutical Holding Company Ltd. Filed Pursuant to 424(b)(5) Registration No. 333-232167 Prospectus Supplement (To Prospectus dated June 17, 2019) Biohaven Pharmaceutical Holding Company Ltd. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 17, 2019 (as supplemented or amended from time to time, the “prospectus”). This prospectus supplement updates and suppl |
|
| March 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| March 15, 2021 |
Filed Pursuant to 424(b)(5) Registration No. 333-232167 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted. |
|
| March 15, 2021 |
CALCULATION OF REGISTRATION FEE Filed Pursuant to 424(b)(7) Registration No. 333-253946 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount Registered Proposed Maximum Offering Price Per Share(1) Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Shares, no par value 107,836 $79.06 $8,525,514.16 $930.13 (1) Estimated solely for purposes of calculating the registration f |
|
| March 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| March 5, 2021 |
As filed with the Securities and Exchange Commission on March 5, 2021 Registration No. |
|
| March 1, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. As of December 31, 2020 Name Jurisdiction of Incorporation Biohaven Specialty Pharmaceutical Ltd. British Virgin Islands Biohaven Therapeutics Ltd. British Virgin Islands Biohaven Pharmaceuticals, Inc. Delaware BioShin Limited British Virgin Islands BioShin Hong Kong Limited Hong Kong BioShin (Shanghai) Consulting Services C |
|
| March 1, 2021 |
Exhibit 99.1 BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS March 1, 2021 ?NURTEC ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020 ?Exceeded market |
|
| March 1, 2021 |
Exhibit 10.1 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(B)(4) and 240.24b-2 FINANCING AGREEMENT dated as of August 7, 2020 as amended by that certain Amendment No. 1 to Financing Agreement dated as of March 1, 2021 among BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. AND BIOHAVEN PHARMACEUTICALS, INC., as Borrowers, THE GUARANTORS FROM TIME TO TIM |
|
| March 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| March 1, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| March 1, 2021 |
As filed with the Securities and Exchange Commission on March 1, 2021 Registration No. |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Biohaven Pharmaceutical Holding Co. Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G11196105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biohaven Pharmaceutical Holding Co. Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G11196105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 26, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| January 26, 2021 |
BIOHAVEN ANNOUNCES PRELIMINARY 4Q2020 NET PRODUCT REVENUE FOR NURTEC® ODT BIOHAVEN ANNOUNCES PRELIMINARY 4Q2020 NET PRODUCT REVENUE FOR NURTEC® ODT - NURTEC® ODT achieved preliminary net product revenue of approximately $35 million for the fourth quarter of 2020, representing an approximately 98% increase from the prior quarter NEW HAVEN, Conn. |
|
| January 8, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2021 Biohaven Pharmaceutical Holding Company Ltd. |
|
| January 8, 2021 |
Exhibit 1.1 Execution Copy AGREEMENT AND PLAN OF MERGER BY AND AMONG BIOHAVEN PHARMACEUTICAL HOLDING COMPANY, LTD., BIOHAVEN THERAPEUTICS LTD., KLEO ACQUISITION, INC., KLEO PHARMACEUTICALS, INC. AND Shareholder Representative Services LLC, AS THE STOCKHOLDERS’ REPRESENTATIVE DATED AS OF JANUARY 1, 2021 TABLE OF CONTENTS Page Article I. DEFINITIONS. 2 Section 1.1. Definitions 2 Section 1.2. Interpr |
|
| January 8, 2021 |
Exhibit 99.1 BIOHAVEN ACQUIRES KLEO PHARMACEUTICALS AND LICENSES PLATFORM TECHNOLOGY FROM YALE UNIVERSITY TO FORM BIOHAVEN LABS •Acquires full ownership of Kleo Pharmaceuticals with two novel immune modulating platforms: the Multi-targeted Antibody Therapy Enhancer (MATE™) conjugation platform and Antibody Recruiting Molecule (ARM™) platform •Enters into exclusive license agreement with Yale Unive |
|
| December 23, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| December 23, 2020 |
CALCULATION OF REGISTRATION FEE Filed Pursuant to 424(b)(5) Registration No. 333-232167 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Shares, no par value per common share $ 400,000,000 $ 43,640.00 (1)The proposed maximum aggregate offering price is being used to calculate the registration fee pursuant to Rule 4 |
|
| December 23, 2020 |
, 2020, by and between Biohaven Pharmaceutical Holding Company Ltd. and Goldman Sachs & Co. LLC Exhibit 1.1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. Common Shares (without par value) Having an Aggregate Offering Price of up to $400,000,000 Equity Distribution Agreement December 23, 2020 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Piper Sandler & Co. LLC 100 Federal Street Boston, MA 02110 SVB Leerink LLC One Federal Street, 37th Floor Boston, MA 02110 Canaccord Genui |
|
| November 9, 2020 |
Exhibit 10.2 AMENDMENT NO. 1 TO FUNDING AGREEMENT This Amendment No. 1 to Funding Agreement (this “Amendment”), is entered into on August 7, 2020, by and between Biohaven Pharmaceutical Holding Company Ltd., a business company organized under the laws of the British Virgin Islands (the “Seller”), Biohaven Pharmaceuticals Ireland DAC, a designated activity company organized under the laws of Irelan |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| November 9, 2020 |
Exhibit 10.1 FINANCING AGREEMENT dated as of August 7, 2020 among BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. AND BIOHAVEN PHARMACEUTICALS, INC., as Borrowers, THE GUARANTORS FROM TIME TO TIME PARTY HERETO, as Guarantors, VARIOUS LENDERS FROM TIME TO TIME PARTY HERETO, AND SIXTH STREET SPECIALTY LENDING, INC., as Administrative Agent US-DOCS\116826573.25 TABLE OF CONTENTS Page Article I DEFINITIO |
|
| November 9, 2020 |
Exhibit 10.3 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. SERIES B PREFERRED SHARE PURCHASE AGREEMENT THIS SERIES B PREFERRED SHARE PURCHASE AGREEMENT (the “Agreement”) is made as of August 7, 2020 (the “Execution Date”) by and between Biohaven Pharmaceutical Holding Company Ltd., a BVI business company organized under the laws of the British Virgin Islands (the “Company”), and RPI 2019 Intermedia |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| November 9, 2020 |
Exhibit 10.1 Funding Agreement By and Between Biohaven Pharmaceutical Holding Company Ltd. and RPI 2019 Intermediate Finance Trust Dated as of August 7, 2020 TABLE OF CONTENTS Page ARTICLE 1 PURCHASE, SALE AND ASSIGNMENT OF THE REVENUE PARTICIPATION RIGHT 1 Section 1.1 Purchase, Sale and Assignment 1 Section 1.2 Initial Purchase Price 1 Section 1.3 No Assumed Obligations, Etc. 1 Section 1.4 Series |
|
| November 9, 2020 |
Exhibit 99.1 BIOHAVEN REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS –NURTEC™ ODT (rimegepant) achieved net revenues of $17.7 million for the third quarter of 2020, representing an over 80% increase in net revenues from the second quarter of this year –NURTEC ODT preventive treatment of migraine sNDA filing accepted by the FDA with PDUFA goal date in second quarter o |
|
| August 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| August 18, 2020 |
British Virgin Islands The BVI Business Companies Act (No. 16 of 2004) Memorandum and Articles of Association of Biohaven Pharmaceutical Holding Company Ltd. Incorporated this 25th day of September 2013 Amended and Restated this 20th day of January 2014 Amended and Restated this 28th day of June 2016 Amended and Restated this 28th day of October 2016 Amended this 21st day of April 2017 Amended and |
|
| August 10, 2020 |
Exhibit 99.1 BIOHAVEN REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS –NURTEC™ ODT (rimegepant) achieved net revenues of $9.7M for the second quarter of 2020 –Company well-capitalized with recent non-dilutive financing of up to $950M from Sixth Street term loan and Royalty Pharma funding agreement –Remains on timelines for NURTEC ODT sNDA filing for prevention of mig |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| June 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| June 12, 2020 |
Biohaven Appoints Bob Hugin to its Board of Directors Exhibit 99.1 Biohaven Appoints Bob Hugin to its Board of Directors - Former Chief Executive Officer and Executive Chairman of Celgene Corporation brings deep leadership experience to Biohaven Board NEW HAVEN, Conn., June 10, 2020 /PRNewswire/ - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced the appointment of pharmaceutical industry leader Robert J. Hugin to its Board o |
|
| June 2, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| June 2, 2020 |
biohaveninvestorpresenta Exhibit 99.1 neuroinnovation Meeting Patient Needs Growing Value INVESTOR PRESENTATION | JUNE 2020 NYSE: BHVN © 2020 Biohaven Pharmaceuticals Inc. All rights reserved. Disclaimer This presentation contains forward-looking statements within the meaning of “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995, including: statements about Biohaven P |
|
| May 19, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 7, 2020 |
Exhibit 99.1 BIOHAVEN PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS –NURTEC™ ODT (rimegepant) received FDA-approval for acute treatment of migraine on February 27, 2020 and Biohaven reports net revenues of $1.2M in March 2020 after launch in U.S. Pharmacies –In the first full six weeks following launch, NURTEC ODT had the greatest week-over-week grow |
|
| May 7, 2020 |
Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act. Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Vlad Coric, M.D., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2020 of Biohaven Pharmaceutical Holding Company Ltd. (the “registrant”); 2. Based on my knowledge, this report does not contain any untrue statement of a material f |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 7, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| April 30, 2020 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| April 17, 2020 |
Amended and Restated Memorandum and Articles of Association of the Registrant. Exhibit 3.1 British Virgin Islands The BVI Business Companies Act (No. 16 of 2004) Memorandum and Articles of Association of Biohaven Pharmaceutical Holding Company Ltd. Incorporated this 25th day of September 2013 Amended and Restated this 20th day of January 2014 Amended and Restated this 28th day of June 2016 Amended and Restated this 28th day of October 2016 Amended this 21st day of April 2017 |
|
| April 17, 2020 |
BIOHAVEN Changing 2020 Annual Meeting of Shareholders to Virtual-Only Meeting Format due to COVID-19 EX-99.1 3 tm2016123d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BIOHAVEN Changing 2020 Annual Meeting of Shareholders to Virtual-Only Meeting Format due to COVID-19 NEW HAVEN, Connecticut, April 16, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that its Board of Directors has decided to hold the company's 2020 Annual Meeting of Shareholders on Thursday, Ap |
|
| April 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| April 16, 2020 |
BHVN / Biohaven Pharmaceutical Holding DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 31, 2020 |
Exhibit 99.2 NEURO INNOVATION BROAD PIPELINE OF LATE STAGE PRODUCT CANDIDATES NYSE: BHVN © 2020 Biohaven Pharmaceuticals Inc. All rights reserved. Rimegepant Migraine Prevention Topline Data Webcast March 30, 2020 Multiple Approaches Targeted for Acute & Preventive Treatment of Migraine MARCH 30, 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES 2 NO JECTION™ CGRP Drug Delivery Platfor |
|
| March 31, 2020 |
Exhibit 99.1 Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC™, Dosed Every Other Day, for the Preventive Treatment of Migraine - Rimegepant 75 mg, dosed every other day, demonstrates statistically significant superiority, compared to placebo, on the primary endpoint of reduction in the mean number of migraine days per month - Orally administered rimegepant 75 mg, approved earlie |
|
| March 31, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| March 20, 2020 |
BHVN / Biohaven Pharmaceutical Holding DEF 14A - - DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 4, 2020 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| March 4, 2020 |
Letter of PricewaterhouseCoopers LLP, dated March 4, 2020 Exhibit 16.1 March 4, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Biohaven Pharmaceutical Holding Company Ltd. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Biohaven Pharmaceutical Holding Company Ltd. dated February 27, 2020. |
|
| February 28, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| February 28, 2020 |
Investor Presentation, dated February 28, 2020, titled “NURTEC™ ODT Investor Webcast” Exhibit 99.2 © 2018 Biohaven Pharmaceuticals. All rights reserved. Nurtec™ ODT Investor Webcast FEBRUARY 28, 2020NYSE: BHVN Now FDA Approved 2 FEB 2020 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES Sustained response up to 48 hours. Half-life of 11 hours. One Dose. Anytime. Anywhere. No titration needed. Quick-dissolve ODT can start working in minutes IMPORTANT SAFETY INFORMATION Contra |
|
| February 28, 2020 |
Exhibit 99.1 BIOHAVEN’S NURTEC™ ODT (RIMEGEPANT) RECEIVES FDA APPROVAL FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS – First and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) – A single oral dose of NURTEC ODT 75 mg can provide fast pain relief and return patients to normal function within one hour, and deliver sustain |
|
| February 26, 2020 |
EXECUTION VERSION Exhibit 10.28 Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K The omitted information is (i) not material and (ii) would likely cause competitive harm to Biohaven Pharmaceutical Holding Company Ltd. if publicly disclosed. Information that has been omitted has been noted in this document with a placeholder identified by the mark “[* |
|
| February 26, 2020 |
Exhibit 10.25 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "Agreement") is entered into on this day of March 30, 2019 by and between BIOHAVEN PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and WILLIAM JONES, JR., an individual resident of the Commonwealth of Pennsylvania (the "Executive"). WHEREAS, the Company is an indirect subsidiary of Biohaven Pharmaceutical Holding Comp |
|
| February 26, 2020 |
Offer Letter dated April 5, 2017 by and between Biohaven Pharmaceuticals, Inc. and Elyse Stock. Exhibit 10.27 February 21, 2017 Elyse Stock M.D. RE: LETTER OF OFFER OF EMPLOYMENT – Chief of Strategy and Portfolio Development Dear Elyse, Following our recent discussions, we are delighted to offer you the position of Chief of Strategy and Portfolio Development with Biohaven Pharmaceuticals, Inc. We are confident you will find this new opportunity both challenging and rewarding. The following p |
|
| February 26, 2020 |
Exhibit 10.26 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”) is made as of February 1, 2014 by and between Biohaven Pharmaceuticals, Inc., a Delaware corporation with an office at 234 Church Street, Suite 304, New Haven, Connecticut 06510 and its affiliates and subsidiaries (collectively the “Company”) and Ms. Kimberly A. Gentile (the “Executive”) of 7 Timber Lane Ellington, CT 06029 |
|
| February 26, 2020 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. Name Jurisdiction of Incorporation Biohaven Pharmaceuticals, Inc. Delaware Biohaven Asia Pacific Ltd. British Virgin Islands BioShin Hong Kong Limited Hong Kong Biohaven Therapeutics Ltd. British Virgin Islands Biohaven Ireland Limited Ireland |
|
| February 26, 2020 |
Description of Biohaven's Securities Registered under Section 12 of the Exchange Act. Exhibit 4.3 Description of Biohaven Pharmaceutical Holding Company Ltd.’s Securities Registered Under Section 12 of the Exchange Act The following summary of the common shares of Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, “we” or “us”) is based on and qualified by our amended and restated memorandum and articles of association (“memorandum and articles of association”). Please note |
|
| February 26, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| February 26, 2020 |
Exhibit 99.1 BIOHAVEN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS February 25, 2020 –Prescription Drug User Fee Act (PDUFA) date for rimegepant Zydis® orally dissolving tablet (ODT) set for 1Q2020 and Company prepared for commercialization –Company well-capitalized with $316.7 million in available cash at the end of 2019 and in addit |
|
| February 26, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| January 31, 2020 |
BIOHAVEN APPOINTS Michael heffernan TO BOARD OF DIRECTORS Exhibit 99.1 BIOHAVEN APPOINTS Michael heffernan TO BOARD OF DIRECTORS NEW HAVEN, Connecticut, January 31, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the appointment of Michael Heffernan to its Board of Directors (“Board”). Mr. Heffernan is a seasoned biopharmaceutical leader with over 25 years of commercial experience. Mr. Heffernan is a pharmaci |
|
| January 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| January 30, 2020 |
Exhibit 1.1 EXECUTION VERSION 4,830,917 Shares BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. COMMON SHARES, WITHOUT PAR VALUE UNDERWRITING AGREEMENT January 28, 2020 January 28, 2020 Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198 Ladies and Gentlemen: Biohaven Pharmaceutical Holding Company Ltd., a British Virgin Islands (“BVI”) business company (the “Company”), proposes to |
|
| January 30, 2020 |
Filed Pursuant to 424(b)(5) Registration No. 333-232167 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be Registered(1) Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Shares, no par value 5,555,554 $51.75 $287,499,920 $37,318 (1) Includes 724,637 Common Shares that the underwriter has the option to purcha |
|
| January 30, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| January 28, 2020 |
Filed Pursuant to 424(b)(5) Registration No. 333-232167 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted. |
|
| January 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 Biohaven Pharmaceutical Holding Company Ltd. |
|
| January 13, 2020 |
Exhibit 99.1 NYSE: BHVN © 2019 Biohaven Pharmaceuticals Inc. All rights reserved. NEURO INNOVATION Meeting Patient Needs. Growing Value. INVESTOR PRESENTATION | JANUARY 2020 Disclaimer This presentation contains forward - looking statements within the meaning of “safe harbor” provisions of The Private Securities L itigation Reform Act of 1995, including: statements about Biohaven Pharmaceutical Ho |
|
| November 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| November 1, 2019 |
Exhibit 99.1 BIOHAVEN PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS November 1, 2019 - Announced acceptance by the United States Food and Drug Administration (FDA) of the new drug applications (NDAs) for rimegepant and expected Prescription Drug User Fee Act (PDUFA) date of the first quarter of 2020 for the Zydis® orally dissolving tablet (ODT) formu |
|
| November 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| October 3, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| October 3, 2019 |
Exhibit 99.1 NEURO INNOVATION BROAD PIPELINE OF LATE STAGE PRODUCT CANDIDATES NYSE: BHVN © 2019 Biohaven Pharmaceuticals Inc. All rights reserved. Biohaven Investor Presentation October 3, 2019 Disclaimer SEPTEMBER 2019 ADVANCING INNOVATIVE THERAPIES FOR NEUROLOGICAL DISEASES - BIOHAVEN IR 2 This presentation contains forward - looking statements within the meaning of “safe harbor” provisions of T |
|
| September 4, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| September 4, 2019 |
EXHIBIT 99.1 NEUROINNOVATION BROAD PIPELINE OF LATE STAGE PRODUCT CANDIDATES Wells Fargo Healthcare Conference Investor Presentation September 2019 NYSE: BHVN © 2019 Biohaven Pharmaceuticals Inc. All rights reserved. Disclaimer This presentation contains forward-looking statements within the meaning of "safe harbor" provisions of The Private Securities Litigation Reform Act of 1995, including: sta |
|
| August 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biohaven Pharmaceutical Holding Company Ltd. (Exact name of Registrant as specified in its charter) British Virgin Islands Not applicable (State or other jurisdiction of Incorporation or organization) (I.R.S. Employer Identification No.) c/o Biohaven Pharmaceutic |
|
| August 9, 2019 |
Exhibit 99.1 BIOHAVEN PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS August 9, 2019 - Submitted Two New Drug Applications (NDAs) to FDA for Zydis® Orally Dissolving Tablet (ODT) and tablet formulations of rimegepant in the second quarter of 2019 - Applied Biohaven’s Priority Review Voucher (PRV) to the rimegepant Zydis® ODT NDA, providing an expedite |
|
| August 9, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| August 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| August 8, 2019 |
Exhibit 99.1 BIOHAVEN PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS August 8, 2019 - Submitted Two New Drug Applications (NDAs) to FDA for Zydis® Orally Dissolving Tablet (ODT) and tablet formulations of rimegepant in the second quarter of 2019 - Applied Biohaven’s Priority Review Voucher (PRV) to the rimegepant Zydis® ODT NDA, providing an expedite |
|
| August 8, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| June 21, 2019 |
Exhibit 1.1 6,976,745 Shares BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. COMMON SHARES, WITHOUT PAR VALUE UNDERWRITING AGREEMENT June 18, 2019 Goldman Sachs & Co. LLC, Piper Jaffray & Co. As Representatives of the several Underwriters listed on Schedule I hereto c/o Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198 c/o Piper Jaffray & Co. 345 Park Avenue, 12th Floor New York |
|
| June 21, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| June 20, 2019 |
Filed Pursuant to 424(b)(5) Registration No. 333-232167 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be Registered(1) Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Shares, no par value 8,023,256 $43.00 $345,000,008 $41,814 (1) Includes 1,046,511 Common Shares that the underwriters have the option to pu |
|
| June 18, 2019 |
Filed Pursuant to 424(b)(5) Registration No. 333-232167 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted. |
|
| June 17, 2019 |
EX-10.4 5 exhibit104-2019junebhvnsx3.htm EXHIBIT 10.4 Exhibit 10.4 AMENDMENT AND ASSIGNMENT This AMENDMENT AND ASSIGNMENT (“Amendment”) dated as of May 29, 2019 among ALS Biopharma, LLC (“ALS”), Fox Chase Chemical Diversity Center (“FCCDC”), and Biohaven Pharmaceutical Holding Company Ltd (“Biohaven”) and Biohaven Therapeutics Ltd. (“Therapeutics”), each designated a “Party” and collectively the “ |
|
| June 17, 2019 |
Exhibit 4.3 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. ——————————— INDENTURE Dated as of , 2019 ——————————— [ ] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1 Definitions. 2 Section 1.2 Other Definitions. 5 Section 1.3 Incorporation by Reference of Trust Indenture Act. 6 Section 1.4 Rules of Construction. 6 ARTICLE II THE SECURITIES Section 2.1 Is |
|
| June 17, 2019 |
Exhibit 10.7 Certain portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K The omitted information is (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. Information that has been omitted has been noted in this document with a placeholder identified by the mark “[***]”. TABLE OF CONTENTS 1. BACKGROUND 2 2. DEFINITIO |
|
| June 17, 2019 |
BHVN / Biohaven Pharmaceutical Holding S-3ASR - - S-3ASR S-3ASR 1 a2019junebhvns-3asr.htm S-3ASR As filed with the Securities and Exchange Commission on June 17, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biohaven Pharmaceutical Holding Company Ltd. (Exact name of registrant as specified in its charter) British Virgin Islands (State o |
|
| May 22, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 8, 2019 |
Exhibit 99.1 [LOGO] Disclaimer This presentation contains forward-looking statements within the meaning of “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995, including: statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our rimegepant, BHV-3500, troriluzole, BHV-0223, BHV-5000 and BHV-3241 development progr |
|
| May 8, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 8, 2019 |
Exhibit 10.1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. SERIES A PREFERRED SHARE PURCHASE AGREEMENT THIS SERIES A PREFERRED SHARE PURCHASE AGREEMENT (the “Agreement”) is made as of March 18, 2019 (the “Execution Date”) by and between Biohaven Pharmaceutical Holding Company Ltd., a BVI business company organized under the laws of the British Virgin Islands (the “Company”), and RPI Finance Trust, |
|
| May 7, 2019 |
Exhibit 99.1 5/7/2019 BIOHAVEN PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND ADVANCEMENTS IN NEUROINNOVATION PLATFORMS ▪ Secured Priority Review Voucher (PRV) enabling expedited regulatory review of rimegepant Zydis® ODT New Drug Application (NDA) ▪ Completed $125 million preferred stock sale to Royalty Pharma ▪ Continued enrollment in oral rimegepant Phase 3 trial for the preve |
|
| May 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 7, 2019 |
Exhibit 99.3 2019 American Academy of Neurology (AAN) Annual Meeting | May 4-10 | Philadelphia, PA References: 1. Miller RG, Mitchell JD, Moore DH. Cochrane Database Syst Rev. 2012;(3):CD001447. 2. Fang T, Khleifat AA, Meurgey JH, et al. Lancet Neurol. 2018;17:416-422. 3. Mandrioli J, Malerba SA, Beghi E, et al. J Neurol. 2018;265:817-827. Disclosures: GJL, IAQ, and RB are employees and shareholde |
|
| May 7, 2019 |
Exhibit 99.1 [LOGO]2019 American Academy of Neurology (AAN) Annual Meeting | May 4-10 | Philadelphia, PA Efficacy, Safety, and Tolerability of Rimegepant 75 mg Orally Dissolving Tablet for the Acute Treatment of Migraine: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial (Study 303) Richard B. Lipton, MD1; Vladimir Coric, MD2; Elyse G. Stock, MD2; David A. Stock, PhD2; Alexandra C. Thi |
|
| May 7, 2019 |
Exhibit 99.4 2019 AmericanAcademy of Neurology(AAN) Annual Meeting |May 4-10 | Philadelphia, PA References: 1.HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2016. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/nisoverview.jsp.2. Dubinsky R, Chen J, Lai SM. Neurology. 2006;67:777-780. 3. LechtzinN, Wiener CM, Clawson L, et al. |
|
| May 7, 2019 |
Exhibit 99.2 2019 American Academy of Neurology (AAN) Annual Meeting | May 4-10 | Philadelphia, PA References: 1. Protocol BHV4157-201, A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects with Spinocerebell.Biohaven Pharmaceutical Holding Company Limited, 2017. 2. Ashizawa T, Figueroa KP, Perlman SL, et al. Orphanet J Rare Dis. 2013;8:177. Disclosures: |
|
| May 7, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| May 1, 2019 |
BHVN / Biohaven Pharmaceutical Holding DEFA14A DEFA14A DEFA14A 1 a2019bhvnxdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 11, 2019 |
BHVN / Biohaven Pharmaceutical Holding DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 11, 2019 |
BHVN / Biohaven Pharmaceutical Holding DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| April 8, 2019 |
Amended and Restated Memorandum and Articles of Association (Exhibit 3.1) Exhibit 3.1 British Virgin Islands The BVI Business Companies Act (No. 16 of 2004) Memorandum and Articles of Association of Biohaven Pharmaceutical Holding Company Ltd. Incorporated this 25th day of September 2013 Amended and Restated this 20th day of January 2014 Amended and Restated this 28th day of June 2016 Amended and Restated this 28th day of October 2016 Amended this 21st day of April 2017 |
|
| March 18, 2019 |
Exhibit 2.1 PRV TRANSFER AGREEMENT BY AND BETWEEN BIOHAVEN PHARMACEUTICAL HOLDING LTD AND GW RESEARCH, LTD. March 15, 2019 PRV TRANSFER AGREEMENT This PRV TRANSFER AGREEMENT (this “Agreement”) is made and entered into as of March 15, 2019 (the “Effective Date”), by and between Biohaven Pharmaceutical Holding Ltd, including its Affiliates (collectively “Buyer”) and GW Research, Ltd., including its |
|
| March 18, 2019 |
Exhibit 99.1 BIOHAVEN SECURES PRIORITY REVIEW VOUCHER (PRV) TO EXPEDITE REGULATORY REVIEW OF RIMEGEPANT ZYDIS ODT NEW DRUG APPLICATION ·Rimegepant Zydis orally disintegrating tablet (ODT) is Biohaven’s lead oral CGRP receptor antagonist drug candidate from its NOJECTION™ migraine platform ·A priority review voucher (PRV) entitles the holder to designate a New Drug Application (NDA) for priority re |
|
| March 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| February 28, 2019 |
Exhibit 99.1 February 28, 2019 BIOHAVEN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL AND RECENT BUSINESS RESULTS •Positioned to submit New Drug Applications (NDA) for rimegepant Zydis ODT and tablet formulations for the acute treatment of migraine in 2Q2019 •Anticipate completion of Phase 3 trial of rimegepant preventive treatment of migraine trial in 2Q2019 •Intend to initi |
|
| February 28, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2019 Biohaven Pharmaceutical Holding Company Ltd. |
|
| February 28, 2019 |
Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. Name Jurisdiction of Incorporation Biohaven Pharmaceuticals, Inc. Delaware Biohaven Asia Pacific Ltd. British Virgin Islands BioShin Hong Kong Limited Hong Kong Biohaven Therapeutics Ltd. British Virgin Islands |
|
| February 28, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38080 Biohaven Pharmaceutical Holding Company Ltd. |
|
| February 14, 2019 |
BHVN / Biohaven Pharmaceutical Holding / RA Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biohaven Pharmaceutical Holding Company Ltd. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) G11196105 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 14, 2019 |
BHVN / Biohaven Pharmaceutical Holding / Vivo Capital VIII, LLC - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) * Biohaven Pharmaceutical Holding Co Ltd. (Name of Issuer) Common Stock (Title of Class of Securities) G1196105 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| December 21, 2018 |
Prospectus Supplement No. 3 (to Prospectus dated October 2, 2018) Filed Pursuant to 424(b)(3) Registration No. 333-227670 109,523 Shares Common Shares This prospectus supplement (“Prospectus Supplement No. 3”) updates and should be read in conjunction with the prospectus dated October 2, 2018 (the “Prospectus”) relating to the resale or other disposition, from time to time, by the selling sharehol |
|
| December 21, 2018 |
424B3 1 a2018dec21bhvn424b3452018d.htm 424B3 Prospectus Supplement No. 7 (to Prospectus dated April 5, 2018) Filed Pursuant to 424(b)(3) Registration No. 333-224123 2,000,000 Shares Common Shares This prospectus supplement (“Prospectus Supplement No. 7”) updates and should be read in conjunction with the prospectus dated April 5, 2018 (the “Prospectus”) relating to the resale or other disposition, |
|
| December 21, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2018 Biohaven Pharmaceutical Holding Company Ltd. |
|
| December 21, 2018 |
Exhibit 99.1 BIOHAVEN ANNOUNCES CLOSING OF $144M PUBLIC OFFERING OF COMMON SHARES, INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES December 17, 2018 NEW HAVEN, Conn., Dec. 17, 2018 /PRNewswire/ - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage |
|
| December 14, 2018 |
3,355,705 Shares COMMON SHARES Filed Pursuant to 424(b)(4) Registration No. 333-228736 Registration No. 333-228768 PROSPECTUS 3,355,705 Shares COMMON SHARES Biohaven Pharmaceutical Holding Company Ltd. is offering 3,355,705 of its common shares at an offering price per share of $37.25. Our common shares are listed on the New York Stock Exchange under the symbol “BHVN.” The last reported sale price of our common shares on the Ne |
|
| December 13, 2018 |
BHVN / Biohaven Pharmaceutical Holding S-1MEF As filed with the Securities and Exchange Commission on December 12, 2018 Registration No. |
|
| December 10, 2018 |
BHVN / Biohaven Pharmaceutical Holding S-1 As filed with the Securities and Exchange Commission on December 10, 2018 Registration No. |
|
| December 10, 2018 |
Form of Underwriting Agreement. Exhibit 1.1 [●] Shares BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. COMMON SHARES, WITHOUT PAR VALUE UNDERWRITING AGREEMENT December [●], 2018 December [●], 2018 Goldman Sachs & Co. LLC, Piper Jaffray & Co. As Representatives of the several Underwriters listed on Schedule I hereto c/o Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198 c/o Piper Jaffray & Co. 345 Park Avenue, 1 |
|
| December 10, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2018 Biohaven Pharmaceutical Holding Company Ltd. |
|
| December 10, 2018 |
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study Exhibit 99.1 Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study · Over 91,000 doses of rimegepant 75mg administered across 1,780 patients with migraine · Safety and tolerability profile of rimegepant with up to one year of dosing in patients with migraine is consistent with previous Phase 1-3 clinical experience · No liver safety signal detected, including a subset |
|
| December 10, 2018 |
BHVN / Biohaven Pharmaceutical Holding CORRESP 215 Church Street New Haven, CT 06510 VIA EDGAR December 10, 2018 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Gabor Re: Biohaven Pharmaceutical Holding Company Ltd. Registration Statement on Form S-1 File No. 333-228736 Acceleration Request Requested Date: Wednesday, December 12, 2018 Requested Time: 4:30 P.M. East |
|
| December 10, 2018 |
BHVN / Biohaven Pharmaceutical Holding CORRESP December 10, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Biohaven Pharmaceutical Holding Company Ltd. Registration Statement on Form S-1 (SEC File No. 333-228736) Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as |
|
| December 3, 2018 |
2,000,000 Shares Common Shares Prospectus Supplement No. 6 Filed Pursuant to 424(b)(3) (to Prospectus dated April 5, 2018) Registration No. 333-224123 2,000,000 Shares Common Shares This prospectus supplement (“Prospectus Supplement No. 6”) updates and should be read in conjunction with the prospectus dated April 5, 2018 (the “Prospectus”) relating to the resale or other disposition, from time to time, by the selling shareholde |
